Niagen Bioscience (NAGE) FDA Approvals $2.04 +0.03 (+1.49%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$2.04 0.00 (-0.25%) As of 11/17/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Niagen Bioscience's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Niagen Bioscience (NAGE). Over the past two years, Niagen Bioscience has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NB4168. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NB4168 FDA Regulatory Events NB4168 is a drug developed by Niagen Bioscience for the following indication: Treatment Of Ataxia Telangiectasia. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - August 3,2026Provided Update Drug: NB4168Announced Date: August 3, 2026Indication: Treatment Of Ataxia TelangiectasiaAnnouncementNiagen Bioscience, Inc announced that it has selected Evotec a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168.AI SummaryNiagen Bioscience reported new human research suggesting that its nicotinamide riboside (NR) supplement, Niagen, may help reduce biological aging in skeletal muscle. The study found changes in epigenetic aging markers, indicating that NR may affect how genes linked to aging are regulated, rather than only raising NAD+ levels or supporting mitochondrial activity. Researchers compared the effects of NR and exercise, including high-intensity interval training, across several biological clocks and tissue types. The findings support further study of NAD+ restoration as a potential way to promote healthier muscle aging, although the results remain preliminary and the effects appear complex. Separately, Niagen Bioscience announced that it selected Evotec, a global life science company specializing in drug discovery and development, as a contract research organization for NB4168. Evotec will support the program’s advancement, adding specialized research and development expertise as Niagen continues investigating the candidate.Read AnnouncementDesignation Grant - July 13,2026Designation Grant RPD DesignationDrug: NB4168Announced Date: July 13, 2026Indication: Treatment Of Ataxia TelangiectasiaAnnouncementNNiagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia TelangiectasiaAI SummaryNNiagen Bioscience said its drug candidate NB4168 received Rare Pediatric Disease designation from the U.S. Food and Drug Administration for the treatment of ataxia telangiectasia, a rare and serious disease that mainly affects children. The company said the recognition supports its plan to develop a therapy for a condition with no approved treatments. It also sees the designation as an important sign of support for NB4168 and its broader work in rare disease medicines. Ataxia telangiectasia is a progressive disorder that can cause trouble with movement, immune problems, and other health issues. NNiagen Bioscience said the FDA designation may help speed development and give the program added visibility. The company said it believes NB4168 could become an important new option for patients and families facing this unmet medical need.Read Announcement Niagen Bioscience FDA Events - Frequently Asked Questions Has Niagen Bioscience received FDA approval? As of now, Niagen Bioscience (NAGE) has not received any FDA approvals for its therapy in the last two years. What drugs has Niagen Bioscience submitted to the FDA? In the past two years, Niagen Bioscience (NAGE) has reported FDA regulatory activity for NB4168. What is the most recent FDA event for Niagen Bioscience? The most recent FDA-related event for Niagen Bioscience occurred on August 3, 2026, involving NB4168. The update was categorized as "Provided Update," with the company reporting: "Niagen Bioscience, Inc announced that it has selected Evotec a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168." What conditions do Niagen Bioscience's current drugs treat? Currently, Niagen Bioscience has one therapy (NB4168) targeting the following condition: Treatment Of Ataxia Telangiectasia. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsEikon Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA EventsVeru FDA EventsMedtronic FDA EventsAclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Waldencast FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:NAGE last updated on 8/3/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - August 3,2026Provided Update Drug: NB4168Announced Date: August 3, 2026Indication: Treatment Of Ataxia TelangiectasiaAnnouncementNiagen Bioscience, Inc announced that it has selected Evotec a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168.AI SummaryNiagen Bioscience reported new human research suggesting that its nicotinamide riboside (NR) supplement, Niagen, may help reduce biological aging in skeletal muscle. The study found changes in epigenetic aging markers, indicating that NR may affect how genes linked to aging are regulated, rather than only raising NAD+ levels or supporting mitochondrial activity. Researchers compared the effects of NR and exercise, including high-intensity interval training, across several biological clocks and tissue types. The findings support further study of NAD+ restoration as a potential way to promote healthier muscle aging, although the results remain preliminary and the effects appear complex. Separately, Niagen Bioscience announced that it selected Evotec, a global life science company specializing in drug discovery and development, as a contract research organization for NB4168. Evotec will support the program’s advancement, adding specialized research and development expertise as Niagen continues investigating the candidate.Read Announcement
Designation Grant - July 13,2026Designation Grant RPD DesignationDrug: NB4168Announced Date: July 13, 2026Indication: Treatment Of Ataxia TelangiectasiaAnnouncementNNiagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia TelangiectasiaAI SummaryNNiagen Bioscience said its drug candidate NB4168 received Rare Pediatric Disease designation from the U.S. Food and Drug Administration for the treatment of ataxia telangiectasia, a rare and serious disease that mainly affects children. The company said the recognition supports its plan to develop a therapy for a condition with no approved treatments. It also sees the designation as an important sign of support for NB4168 and its broader work in rare disease medicines. Ataxia telangiectasia is a progressive disorder that can cause trouble with movement, immune problems, and other health issues. NNiagen Bioscience said the FDA designation may help speed development and give the program added visibility. The company said it believes NB4168 could become an important new option for patients and families facing this unmet medical need.Read Announcement